Publications

I have participated in the publication of 48 manuscripts (13 as the first author) and >90 abstracts (37 as presenting author).

For a complete and up-to-date publication list please visit Google Scholar.

2022

Her PH*, Saeed S*, Tram KH, Bhatnagar SR. Novel mobility index tracks COVID-19 transmission following stay-at-home orders. Sci Rep. 2022. 12, 7654  

*Equal contribution

Laniece Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferriere V, Cooper C, Walmsley S, Cox J, Wong A, Klein MB. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Int J Drug Policy. 2022. 103: 103627

 

Sebastiani G, Milic J, Cervo A, Saeed S, Krahn T, Kablawi D, Al Hinai AS, Lebouché B, Wong P, Deschenes M, Gioe C, Cascio A, Mazzola G, Guaraldi G. Two-tier care pathways for liver fibrosis associated to nonalcoholic fatty liver disease in HIV mono-infected patients. J Pers Med. 2022. 12(2): 282

2021

Saeed S, Uzicanin S, Lewin A, Lieshout-Krikke R, Faddy H, Erikstrup E, Osiowy C, Steele WR, Davidson K, Custer B, O’Brien SF. Current challenges of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies among blood donors: A scoping review. Vox Sang. 2021. 1– 12

 

Nguyen QD, Moodie EM, Desmarais P, Goulden R, Forget MF, Peters E, Saeed S, Keezer MR, Wolfson C. Appraising clinical applicability of studies: mapping and synthesis of current frameworks, and proposal of the FrACAS framework and VICORT checklist. BMC Med Res Methodol. 2021. 21(1): 248

 

Saeed S, O’Brien SF, Abe K, Yi Q, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras AC, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLoS One. 2021. 16(9): e0257743

 

Tram KH, Saeed S, Bradley C, Fox B, Eshun-Wilson I, Mody A, Geng E. Deliberation, Dissent, and Distrust: Understanding distinct drivers of COVID-19 vaccine hesitancy in the United States. Clin Infect Dis. 2021 Jul 16: ciab633. doi: 10.1093/cid/ciab633. Epub ahead of print

 

Altit G, Saeed S, Beltempo M, Claveau M, Lapointe A, Basso O. Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches. J Pediatr. 2021. 235: 49-57.e2

 

Palayew A, Schmidt AM, Saeed S, Cooper CL, Wong A, Martel-Laferrière V, Walmsley S, Cox J, Klein MB; Canadian Coinfection Cohort Study Investigators. Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada. PLoS One. 2021. 16(4): e0249836

 

Saeed S, Goldman M, Uzicanin S, O’Brien. Evaluation of a Pre-exposure Prophylaxis (PrEP)/ Post Exposure Prophylaxis (PEP) Deferral Policy among Blood Donors. Transfusion. 2021. 61(6): 1684-1689

 

Saeed S, Drews SJ, Pambrun C, Qi-Long L, Osmond L, O’Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion. 2021. 61(3): 862-872

 

Lewin A, Drews SJ, Lieshout-Krikke R, Erikstrup E, Saeed S, Fady Helene, Steele WR, Uzicanin S, Custer B, O’Brien SF. An International Comparison of Anti-SARS-CoV-2 Assays used for seroprevalence surveys from blood Component Providers. Vox Sang. 2021. 115(9): 946-954

2020

Laniece-Delaunay C, Saeed S, Nguyen Q. Evaluation of testing frequency and sampling for SARS-CoV-2 surveillance strategies in long-term care facilities. J Am Med Dir Assoc. 2020. 21(11): 1574–1576.e2.

 

Sebastiani G, Saeed S, LeBoucher B, de Pokomandy A, Szabo J, Haraoui LP, Routy JP, Wong P, Deschenes M, Ghali P, Klein MB, for the LIVEHIV Study Group. Vitamin E is an Effective Treatment for Non-alcoholic Steatohepatitis in HIV Mono-Infected Patients. AIDS. 2020. 34(2): 237-244

 

Saeed S, Strumpf EC, Moodie EE, Wong L, Cox J, Wong A, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Co-Infection Cohort Study. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV. Clin Inf Dis. 2020. 71(2): 363-71

 

Cousineau SE, Erman A, Liu L, Saeed S, Fradette L, Feld JJ, Grebly J, MacParland SA, Shoukry N, Sagan SM, on behalf of the Canadian Network on Hepatitis C (CanHepC). The 8th Canadian Symposium on Hepatitis C virus: “Improving diagnosis and linkage to care” Canadian Liver Journal 3(1): 3-14

2019

Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade‐Nwulia O, Aspinall E, Hutchinson S, Hellard ME, Sacks‐Davis R. Staying hepatitis C negative: a systematic review and meta‐analysis of cure and reinfection in people who inject drugs. Liver Int. 2019. 39(12): 2244-2260

 

Saeed S, Moodie EE Moodie, Strumpf E, Klein MB. Evaluating the Impact of Health Policies: Using a Difference-in-Differences Approach. Int J Public Health. 2019. 64(4):637-624

 

Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall MW, Wong A, Klein MB. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy. 2019. 65:41-49

2018

Saeed S, Moodie EEM, Strumpf EC, Gill MJ, Wong A, Cooper C, Walmsley S, Hull Mark, Martel-Laferriere V, Klein MB for the Canadian Co-Infection Cohort Study Investigators.  Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life In HIV-Hepatitis C Co-Infected Individuals. Journal of Viral Hepatitis. 2018 25(12):1507-1514

 

Cheng ML, Abdel-Hakeem MS, Cousineau SE, Grebely J, Marshall AD, Saeed S, Sagan SM, Shoukry N, Feld JJ, MacParland SA, on behalf of the Canadian Network on Hepatitis C (CanHepC). The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There” Canadian Liver Journal 2018 (3)139-152

 

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL. Linkage and Retention in HCV Care For HIV-Infected Populations: Emerging Implementation Research. Journal of the International AIDS Society 2018 S2(21):e25051

 

Golizeh M, Melendex-Pena CE, Ward B, Saeed S, Santamaria C, Conway B, Cooper C, Klein MB, Ndao M on behalf of the Canadian Co-Infection Cohort (CTN 222). Proteomic Fingerprinting In HIV/HCV Co-Infection Reveals Serum Biomarkers for The Diagnosis of Fibrosis Staging. PLOS One. 2018 13(4): e0195148

 

Saeed S, Moodie EE Moodie, Strumpf E, Klein MB. Segmented Generalized Mixed Effect Models to Evaluate Health Outcomes. International Journal of Public Health 2018 63(4):547-551

 

Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferriere V, Walmsley S, Cooper C, Gill ML, Moodie EEM, Klein MB, for the Canadian Co-Infection Cohort Study. Hepatitis C Virus Cure Does Not Impact Kidney Function Decline in HIV Co-Infected Patients. AIDS. 2018; 32(6):751-759

2017

Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in Direct Acting Antivirals Uptake In HIV-Hepatitis C Co-Infected Populations in Canada. Journal of the International AIDS Society. 2017; 20(3)

 

Moqueet N, Kanagaratham C, Gill MJ, Hull M, Walmsley S, Radzioch D, Saeed S, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222). A Prognostic Model for Development of Significant Liver Fibrosis In HIV-Hepatitis C Co-Infection. PLoS One. 2017;12(5): e0176282

2016

Saeed S, Strumpf EC, Walmsley S, Rollet-Kurhajec K, Pick N, Martel-Laferriere V, Hull MW, Gill J, Cox J, Cooper C, Klein MB for the Canadian Co-Infection Cohort Study. How Generalizable are the Results from Trials of Direct Antiviral Agents to People Co-Infected With HIV/Hepatitis C Virus in The Real World? Clinical Infectious Disease. 2016; 62(7): 919-26

 

Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Shoukry NH, Taylor LE, Dore GJ, Grebely J, on behalf of the Canadian Network on Hepatitis C (CanHepC). Restrictions for Reimbursement of Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in Canada. CMAJ Open 2016 4(4): E604-E615

 

van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan S. The 5th Canadian Symposium on Hepatitis C Virus: We’re Not Done Yet: Remaining Challenges in Hepatitis C. Canadian Journal of Gastroenterology & Hepatology. 2016:7603526

Prior to 2016

Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell DL, Wilson JA on behalf of the National CIHR Research Training Program in Hepatitis C. The Fourth Canadian Symposium on Hepatitis C: Moving Towards A National Action Plan. Canadian Journal of Gastroenterology & Hepatology. 2015: 5743521

 

Kared H, Saeed S, Klein MB, Shoukry NH. CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. PLoS One 2014; Jul 9; 9(7) e101441

 

Cox, J, Maurais E, Hu L, Moodie EEM, Law S, Bozinoff N, Potter M, Rollet K, Hull M, Tyndall M, Cooper C, Gill J, Saeed S, Klein MB, The Canadian Co-Infection Cohort (CTN 222) Correlates Of Drug Use Cessation Among Participants In The Canadian HIV-HCV Co-Infection Cohort. Drug and Alcohol Dependence. 2014 (137) 121-128

 

Klein MB, Rollet K, Saeed S, Cox J, Potter M, Cohen J, Conway B, Cooper C, Côté P, Gill J, Haase D, Haider S, Hull M, Moodie E, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. HIV And Hepatitis C Virus Co-Infection In Canada: Challenges And Opportunities For Reducing Preventable Morbidity And Mortality. HIV Medicine. 2013; 14(1): 10-20

 

Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB; the Canadian Co-infection Cohort Study Investigators. Insulin Resistance Is Associated with Progression to Hepatic Fibrosis in a Cohort Of HIV/HCV Co-Infected Patients. AIDS. 2012; 10;26(14):1789-94

 

Hull MW, Rollet K, Odueyungbo A, Saeed S, Potter M, Cox J, Cooper C, Gill J, Klein MB; Canadian Co-infection Cohort Investigators. Factors Associated with Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected with HIV And Hepatitis C Virus. Clinical Infectious Disease 2012; 54(12):1798-805

 

Thorpe J, Saeed S, Moodie EE, Klein MB, for the Canadian Co-infection Cohort Study. Interruption of Antiretroviral Therapy (ART) Is Associated with Progression of Liver Fibrosis In HIV/HCV Coinfected Adults. AIDS. 2011; 24;25(7):967-75

 

Rizza SA, Cummins NW, Rider D, Saeed S, Klein MB, Badley AD. Polymorphism in TRAIL Receptor 1 is Associated with Poor Viral Response to Interferon Based HCV Therapy in HIV/HCV Co-Infected Individuals. AIDS. 2010; 13;24(17):2639-44

 

Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, Saeed S, Benko E, Kovacs C, Kaul R, Ostrowski MA.  HCV-Specific T-cells in HCV/HIV Co-infection Show Elevated Frequencies of Dual Tim-3/PD-1 Expression that Correlate with Liver Disease Progression. Eur J Immunol. 2010;40(9):2493-505

 

Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB for the Canadian Co-infection Cohort Study Investigators. Impact of Hepatitis C Viral Replication on CD4+ T-Lymphocyte Progression In HIV-Co-Infection Before and After Antiretroviral Therapy.  AIDS. 2010; 31;24(12):1857-66

 

Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-Infection Cohort Study. International Journal of Epidemiology. 2010; 39(5):1162-9

 

Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Cystic Fibrosis Fatty Acid Imbalance Is Linked to Ceramide Deficiency and Corrected by Fenretinide. American Journal of Respiratory Cell and Molecular Biology 2009;41(1):100-6

 

Saeed Z, Guilbault C, De Sanctis JB, Henri J, Marion D, St-Arnaud R, Radzioch D. Fenretinide Prevents the Development of Osteoporosis in Cftr-KO Mice. Journal of Cystic Fibrosis 2008;7(3):222-30

 

Wojewodka G, C Guilbault, Saeed Z, M Hajduch, E Matouk, JB De Sanctis, D Radzioch. Fenretinide Corrects Fatty Acid Imbalance in CF Mice: A Possible Therapy for CF Patients? Journal of Cystic Fibrosis 2008; 7(S28)

 

Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, Matouk E, Radzioch D. Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular biology 2008;38(1):47-56

 

Saeed Z, Wojewodka G, Marion D, Guilbault C, Radzioch D. Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis. Current Pharmaceutical Design 2007;13(31):3252-63

 

Guilbault C, Saeed Z, Downey GP, Radzioch D. Cystic Fibrosis Mouse Models. American Journal of Respiratory Cell and Molecular 2007;36(1):1-7

 

Guilbault C, Novak JP, Martin P, Boghdady ML, Saeed Z, Guiot MC, Hudson TJ, Radzioch D. Distinct Pattern of Lung Gene Expression In The Cftr-KO Mice Developing Spontaneous Lung Disease Compared With Their Littermate Controls. Physiological Genomics 2006;25(2):179-93